Oakmark Buys AstraZeneca as US Regulatory Fears Create Value
Harris Oakmark added AstraZeneca to its Global Fund in the second quarter, betting that recent US regulatory concerns have created a buying opportunity below the drugmaker's intrinsic value.
Harris Oakmark initiated a position in AstraZeneca during the second quarter, capitalizing on a broader selloff in the pharmaceutical sector. The firm stated that recent concerns over United States regulations have overshadowed the core fundamentals of the multinational drugmaker, creating an entry point for value investors.
The purchase highlights a growing divergence in how money managers are positioning for the second half of 2026. Oakmark's Global Fund returned 7.89% for the quarter, significantly lagging the MSCI World Index's 13.76% rally. Healthcare was a primary drag on the fund's relative performance, alongside consumer discretionary names, while energy and industrials drove gains.
AstraZeneca shares closed at $168.37 on July 15, representing a market capitalization of $261.12 billion. While the stock has generated an 18.55% return over the past 52 weeks, it has dropped 3.75% in the most recent month. Oakmark views this recent dip as a market overreaction rather than a structural issue for the business.
"This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value," the firm wrote in its quarterly update. Oakmark, which prioritizes competitive advantages and long-term cash flow potential over macroeconomic predictions, emphasized AstraZeneca's robust on-market portfolio and its sector-leading late-stage pipeline.
The fund's conviction rests heavily on management execution. "In our view, CEO Pascal Soriot is one of the industry's best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come," the investor letter stated.
For broader market participants, Oakmark's contrarian bet underscores a potential floor for large-cap pharmaceutical stocks. As AI-driven momentum continues to dominate benchmark returns, value-oriented investors are finding opportunities in regulated industries where short-term policy fears have disconnected stock prices from long-term earnings power.
